<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529269</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080AKR03</org_study_id>
    <nct_id>NCT00529269</nct_id>
  </id_info>
  <brief_title>Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms</brief_title>
  <official_title>Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the impact that GI complaints have on patient-reported outcomes and&#xD;
      to determine if there is improvement in patient-reported outcomes when converted from&#xD;
      mycophenolate mofetil (MMF) to Enteric-coated mycophenolate sodium (EC-MPS)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom severity is assessed by the GSRS (GI Symptom Rating Scale); Health-related Quality of Life (HRQL) is assessed by the GIQLI (GI Quality of Life) Index.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of immunosuppressive-induced GI symptoms on patient's perception of symptom severity and HRQL.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Renal Transplant</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-Coated Mycophenolate Sodium (EC-MPS)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Received kidney transplant at least 1 month prior to study enrollment&#xD;
&#xD;
          -  Receiving immunosuppressive regimen that includes MMF for at least 2 weeks prior to&#xD;
             study enrollment&#xD;
&#xD;
          -  Eligible to convert to enteric-coated mycophenolate sodium (EC-MPS) because of GI&#xD;
             complaints OR not currently experiencing GI complaints and stable on current&#xD;
             immunosuppressive regimen&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Willing to provide written informed consent&#xD;
&#xD;
          -  Able to meet all study requirements including completing electronically-administered&#xD;
             questionnaires and completing two study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  GI symptoms assumed or known not to be caused by MPA (Mycophenolic acid) therapy (e.g.&#xD;
             oral biphosphonates induced, infectious diarrhea)&#xD;
&#xD;
          -  Acute rejection &lt; 1 week prior to study enrollment&#xD;
&#xD;
          -  Woman of child-bearing potential who is planning to become pregnant or is pregnant&#xD;
             and/or lactating who is unwilling to use effective means of contraception&#xD;
&#xD;
          -  Presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the&#xD;
             opinion of the site investigator, would interfere with study requirements;&#xD;
&#xD;
          -  Undergoing acute medical intervention or hospitalization&#xD;
&#xD;
          -  Any other medical condition that, in the opinion of the site investigator based on&#xD;
             recall or chart review, would interfere with completing the study, including but not&#xD;
             limited to, visual problems or cognitive impairment&#xD;
&#xD;
          -  Receiving any investigational drug or have received any investigational drug within 30&#xD;
             days prior to study enrollment.&#xD;
&#xD;
        Other protocol-defined inclusion /exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Hwang HS, Hyoung BJ, Kim S, Oh HY, Kim YS, Kim JK, Kim YH, Kim YL, Kim CD, Shin GT, Yang CW. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus. J Korean Med Sci. 2010 Dec;25(12):1759-65. doi: 10.3346/jkms.2010.25.12.1759. Epub 2010 Nov 24.</citation>
    <PMID>21165291</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>September 11, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Transplant Patients, GI symptom, Enteric-coated mycophenolate sodium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

